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Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease characterized
by progressive muscle paralysis determined by the degeneration of motoneurons in
the motor cortex brainstem and spinal cord. The ALS pathogenetic mechanisms are
still unclear, despite the wealth of studies demonstrating the involvement of several
altered signaling pathways, such as mitochondrial dysfunction, glutamate excitotoxicity,
oxidative stress and neuroinflammation. To date, the proposed therapeutic strategies
are targeted to one or a few of these alterations, resulting in only a minimal effect on
disease course and survival of ALS patients. The involvement of different mechanisms in
ALS pathogenesis underlines the need for a therapeutic approach targeted to multiple
aspects. Mesenchymal stem cells (MSC) can support motoneurons and surrounding
cells, reduce inflammation, stimulate tissue regeneration and release growth factors.
On this basis, MSC have been proposed as promising candidates to treat ALS.
However, due to the drawbacks of cell therapy, the possible therapeutic use of
extracellular vesicles (EVs) released by stem cells is raising increasing interest. The
present review summarizes the main pathological mechanisms involved in ALS and the
related therapeutic approaches proposed to date, focusing on MSC therapy and their
preclinical and clinical applications. Moreover, the nature and characteristics of EVs and
their role in recapitulating the effect of stem cells are discussed, elucidating how and
why these vesicles could provide novel opportunities for ALS treatment.
Keywords: amyotrophic lateral sclerosis, ALS therapeutic applications, mesenchymal stem cells, extracellular
vesicles, exosomes
INTRODUCTION
Amyotrophic lateral sclerosis (ALS) is a fatal adult-onset neurodegenerative disease, first described
by the neurobiologist Jean-Martin Charcot in the 1870s and which became initially known as
Charcot’s sclerosis. In the USA, the disease is also known as Lou Gehrig disease, in honor of the
baseball player who developed the disease in the 1930s. ALS has an incidence of 2–3/100,000 and a
prevalence of 6–7/100,000 in Europe (Costa and de Carvalho, 2016), making it the most common
motoneuron disease in human adults (Cleveland and Rothstein, 2001). In 90%–95% of cases there is
no apparent genetic link (sporadic ALS, sALS), while the remaining 5%–10% of cases have a family
history (familial ALS, fALS).
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In general, the first symptoms appear at the mean age of
50 years for fALS, and 60 years for sALS, even if the onset can
occur in very young individuals or in elderly people (Costa and
de Carvalho, 2016). The disease is more common in males than
in females, with an incidence of 1.5:1 (Zarei et al., 2015), although
the incidence in men and women is about the same in fALS. The
disease is fatal within 2–5 years after clinical onset; about 50% of
patients die within 30 months from symptom onset, while about
10% of patients may survive for more than a decade (Forsgren
et al., 1983; del Aguila et al., 2003).
Both sALS and fALS are characterized by selective
degeneration of both upper motoneurons in the primary
motor cortex, and lower motoneurons in the brainstem and
spinal cord. However, some groups of motoneurons, including
those that control pelvic muscles (Onuf’s nucleus in the sacral
spinal cord) and eye movements (oculomotoneurons), are spared
by the pathology. The reasons of this differential motoneuron
vulnerability remain unknown (Comley et al., 2015).
The familial and sporadic forms of the disease appear
clinically indistinguishable. Although the motoneuron
degeneration is the main hallmark of the disease, ALS can
be classified according to the district of symptom onset. Limb
onset is the most common presentation of ALS, with progressive
muscle weakness and wasting, body weight loss, fasciculations,
emotional lability and cognitive dysfunction. In the bulbar
onset, representing approximately 30% of ALS cases, the disease
starts with difficulties in speech and swallowing (dysarthria and
dysphagia), followed by limb symptoms (Pratt et al., 2012).
In sALS, the occurrence of the disease could be also due
to a gene-environment interaction; sALS has been associated
with ‘‘susceptibility’’ genes, that may trigger the cascade of
neurodegeneration interacting with environmental risk factors.
Susceptibility genes could also play a role in fALS, (Zufiría
et al., 2016). Mutations in susceptibility genes could potentially
contribute to the development of the disease only in the presence
of other genetic or environmental factors. In persons with a
susceptibility genotype, the exposure to specific environmental
risk factors may increase the risk for the disease.
Concerning genetic predisposition, epigenetics, and
in particular defects in histone homeostasis (acetylation
and deacetylation), have been implicated in ALS. Histone
acetyltransferases (HATs) and histone deacetylases (HDACs)
catalyze acetylation and deacetylation, respectively, of histone
proteins Lys residues. The interplay between HATs and HDACs
alters the net balance of histone acetylation levels, thereby
remodeling chromatin structure, as indicated by transcriptional
dysregulation that occurs in both ALS murine models and
patients (Janssen et al., 2010). Although a role of epigenetic
alterations in the pathogenesis of ALS has been documented,
it remains to be clarified whether the involved epigenetic
alterations could be related to environmental factors.
Among the risk factors for ALS, lifestyle, including smoking
and dietary factors, and physical activity have been hypothesized.
In particular, some ALS patients have a higher level of physical
fitness and a lower body mass index compared with healthy
controls (Armon, 2003; Turner, 2013). Moreover, environmental
risk factors combined with working conditions (construction
workers, carpenters, farm workers, laboratory technicians and
athletes) could potentially increase the risk for ALS due to
exposure to heavy metals, solvents, pesticides and chemicals
which could contribute to trigger ALS pathogenetic mechanisms
(Ingre et al., 2015).
In a geographical area which includes part of Japan, Guam,
Kii Peninsula of Japan and Guinea the prevalence of the disease
is 50–100 times higher than in any other part of the world.
This increased incidence is ascribed to exposure to a neurotoxic
amino acid, β-methylamino-L-alanine, as indicated by the higher
concentration of this molecule in the brain and spinal cord tissues
of ALS patients than in healthy controls (Pablo et al., 2009).
Viral infections have also been considered as a potential
risk factor for ALS: exposure to viruses such as enterovirus,
herpesvirus and retrovirus may play an important role in the
disease, as reported in studies of blood, serum, muscle and
post-mortem brain tissue of ALS patients. In these tissues a
significant increase of the expression of the virus and the ability
to form virus-like particles were revealed (Berger et al., 2000;
Oluwole et al., 2007; Alfahad and Nath, 2013).
Another important factor to consider is the relationship
between ALS and other medical conditions. Several studies
suggest a strong association of head trauma, metabolic diseases,
autoimmune pathology and neuroinflammation (Chen et al.,
2007; Turner et al., 2013).
Altogether these data point to a substantial impact of
non-genetic factors on ALS. The identification and knowledge
of these factors would be highly relevant for understanding the
etiopathogenesis of the sporadic form of the disease in persons
with a susceptibility genotype.
About 5%–10% of ALS is familial, with a Mendelian pattern
of inheritance. ALS can be inherited in an autosomal dominant,
autosomal recessive or X-linked manner, although in most
affected families it is inherited in an autosomal dominant
manner. Patients with fALS present an earlier age of onset
compared to the sporadic form, and the penetrance, severity,
progression and duration of disease vary in different gene
mutations and different mutations in the same gene (Chen et al.,
2013).
More than 20 gene mutations have been identified in
fALS, which include: Cu/Zn superoxide dismutase 1 gene
(SOD1), TAR DNA-binding protein 43 (TDP43), fused in
sarcoma (FUS)/translocated in sarcoma and ubiquitin 2 (Kaur
et al., 2016). It has been recently reported that the hexarepeat
expansion in chromosome 9 open reading frame 72 (C9orf72) is
the most common inherited cause of fALS (40% of cases; Zufiría
et al., 2016).
Mutations in the SOD1 gene were the first to be identified
in ALS: they occur in up to 20% of fALS cases and in 1%–4%
of sALS cases and, to date, more than 150 mutations have
been found (Chen et al., 2013). Three different isoform of
SOD metalloenzymes are encoded in the human genome: the
cytoplasmic Cu/Zn SOD (SOD1), the mitochondrial Mn SOD
(SOD2) and the extracellular Cu/Zn SOD (SOD3). Each isoform
is a product of distinct genes and has a distinct subcellular
localization, but all require metals for their activity and catalyze
the same reaction: the dismutation of toxic superoxide anion
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radical (O−2 ), a reactive oxygen species (ROS) with a single
unpaired electron produced by cellular respiration, into oxygen
and hydrogen peroxide (H2O2). The toxicity of H2O2 is
then removed by glutathione peroxidase or catalase, which
generates water and oxygen. Therefore, SODs enzymes provide
an important antioxidant defense in cells exposed to oxygen
(Fukai and Ushio-Fukai, 2011).
The human SOD1 isoform, whose gene is located on
chromosome 21 (locus 21q22.1), is a small gene consisting
of five exons and four introns encoding for a homodimeric
enzyme, each monomer formed by 153 amino acids (15.8 kDa)
which form eight antiparallel beta strands. The protein contains
one copper and one zinc atom: the first is fundamental for
SOD1 activity, while zinc plays a role in the structural stability
of the enzyme (Rosen et al., 1993).
The SOD1 mutations can be localized on the beta
strand, determining structural protein instability, or in the
metal-binding sites, determining the lack of Cu and/or
Zn, conformational dysfunction and alteration of protein
interactions. In both instances, the destabilization of the structure
can lead to the formation of aggregates (Kaur et al., 2016).
The majority of SOD1 mutations are associated with an
autosomal dominant form of the disease (ALS1) and G93A,
alanine at codon 4 changed to valine (A4V), H46R and D90A
are the most commonly reported ALS mutations. The G93A
mutation (glycine 93 changed to alanine) is a rare mutation,
but is the most studied as it was the first to be used in a
transgenic mouse model of the disease. The A4V is the most
prevalent mutation in the USA and D90A (aspartic acid at codon
90 changed to alanine) is the most common in Europe (with
either dominant or recessive inheritance).
Gene mutations can cause a dominant gain of function,
resulting in an increase of SOD1 activity, with an excessive
production of H2O2, or in a dominant loss of function with
a decrease in enzyme activity which results in insufficient
degradation of ROS (Kaur et al., 2016).
The main pathogenetic mechanisms involved in motoneuron
degeneration in ALS and the main therapeutic strategies
proposed to date are here summarized. This review article also
focuses on the application of mesenchymal stem cells (MSC) as
treatment for ALS, reporting results obtained in in vivo models of
the disease and in clinical trials. Moreover, extracellular vesicles
(EVs) as possible mediators of a therapeutic effect of stem
cells will be discussed, underlying their potential use for ALS
treatment.
PATHOGENETIC MECHANISMS IN ALS
The identification of molecular mechanisms by which
motoneurons degenerate in ALS is crucial for understanding
disease progression and for the development of new therapeutic
approaches. Although SOD1 mutations have been linked to
ALS since more than two decades, the mechanisms underlying
the mode of action of mutant SOD1 and the subsequent
neurodegeneration/neurotoxicity are still unclear. Several
hypotheses have been proposed in this regards and it seems
likely that the combination of mechanisms, rather than a single
mechanism, contributes to neurodegeneration in ALS, pointing
to a multifactorial pathogenesis (Figure 1).
Mitochondrial Dysfunction
Mitochondrial damage is a common feature of many
neurodegenerative diseases. Mitochondria are the most
important organelles for energy production, cellular respiration
and calcium homeostasis. Moreover, they produce high
level of ROS and play a key role in apoptosis, opening the
permeability transition pore and allowing the release of
cytochrome c, which leads to the activation of the caspase
cascade. For these reasons, structural and biochemical
alterations of mitochondria can be linked to many aspects
of ALS pathogenesis.
Morphological alterations in mitochondria, such as
vacuolated and dilated organelle with disorganized cristae
and membranes, fragmented network and swelling, were
observed in spinal motoneurons and skeletal muscle of both
sALS and fALS patients and in the murine model of the disease
(SOD1(G93A) mice; Boillée et al., 2006a; Sasaki and Iwata,
2007; Magrané and Manfredi, 2009). The formation of vacuoles
is due to expansion of the mitochondrial intermembrane
space and consequent distention of membranes (Higgins et al.,
2003).
Although the mitochondria have own SOD protein (SOD2),
the cytoplasmic SOD protein (SOD1) is also present, at low
levels, in the mitochondrial intermembrane space and in their
matrix (Bergemalm et al., 2006). The deposit of misfolded
mutant SOD1 in mitochondria may alter the physiological
function of these organelles in the cell metabolism. Abnormal
production of ATP and ROS, dysfunction in energy homeostasis
and calcium homeostasis, alteration of apoptosis triggering, as
well as altered mitochondrial transport along axons have been
reported in ALS transgenic mice and patients (Pasinelli et al.,
2000; Mattiazzi et al., 2002; Menzies et al., 2002; Damiano et al.,
2006). Concerning energy homeostasis and ATP deficits, mutant
SOD1 causes a decreased activity of respiratory chain complexes
I and IV which are associated with defective energy metabolism
(Wiedemann et al., 1998). Another key function of mitochondria
concerns the regulation of cytosolic calcium levels: several studies
reported a loss of Ca2+ binding proteins in motoneurons of
ALS patients related to the presence of mutant SOD1 (Bernard-
Marissal et al., 2012; Mattson, 2013), which leads to reduced
calcium uptake from the cytoplasm, increasing the sensitivity to
excitotoxicity.
Moreover, mitochondria are required in areas with high
demand of ATP and calcium homeostasis, such as synaptic
terminals. Therefore, transport of mitochondria to these areas
is of primary importance, and defects in mitochondrial axonal
transport lead to metabolic alterations in neurons (Magrané and
Manfredi, 2009; Mòrotz et al., 2012).
Altered protein expression in mutant mitochondria has also
been reported (Fukada et al., 2004; Kirby et al., 2005; Lukas et al.,
2006). Since the majority of proteins required for the function of
this organelle are synthesized in the cytoplasm and imported in
the mitochondria, mutant SOD1 associated to the mitochondrial
surface could prevent protein import (Liu et al., 2004).
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FIGURE 1 | Pathogenetic mechanisms involved in amyotrophic lateral sclerosis (ALS). The pathophysiological mechanism of the disease appears to be
multifactorial and several mechanisms contribute to neurodegeneration. An increase of the neurotransmitter glutamate in the synaptic cleft (glutamate excitotoxicity),
due to the impairment of its uptake by astrocytes, leads to an increased influx of Ca2+ ions in the motoneurons. The increased levels of Ca2+ ions, which in
physiological conditions could be removed by mitochondria (calcium homeostasis), remain high in the cytoplasm due to mitochondrial dysfunction and can cause
neurodegeneration through activation of Ca2+-dependent enzymatic pathways contributing to oxidative stress. Mutant misfolding proteins (such as superoxide
dismutase 1 gene (SOD1), chromosome 9 open reading frame 72 (C9orf72), TAR DNA-binding protein 43 (TDP-43) and fused in sarcoma (FUS) form intercellular
aggregates, contribute to an increase of oxidative stress, contribute to mitochondrial dysfunction and could lead to the accumulation of neurofilaments (NFs) and
dysfunction of axonal transport. Moreover, activated astrocyte and microglia release inflammatory mediators and toxic factors, contributing to neurotoxicity.
Glutamate Excitotoxicity
Glutamate, the main excitatory neurotransmitter in the central
nervous system (CNS), is synthesized in the presynaptic
terminal and diffuses across the synaptic cleft, activating specific
postsynaptic receptors and triggering action potentials. This
neurotransmitter acts on different receptors on the dendrites
of the postsynaptic motoneuron, such as α-amino-3-hydroxyl-
5-methyl-4-isoxazole-propionate (AMPA) and N-methyl-D-
aspartate (NMDA) receptors. The depolarization of neuronal
membranes after activation of neuronal glutamate receptors
activates voltage-dependent calcium channels, allowing calcium
to enter the cell.
After release from the presynaptic neuron, glutamate is
removed from the synaptic cleft by several glial and neuronal cell
transporter proteins, excitatory amino acid transporters (EAATs;
Sundaram et al., 2012). The concentration of glutamate in the
synaptic cleft is thus finely regulated, avoiding excitotoxicity:
an excessive or prolonged activation of glutamate receptors
results in degeneration and eventually death of the involved
neurons (Shaw and Eggett, 2000). A sustained elevation of
intracellular calcium levels triggers enzymatic and mitochondrial
damages that lead to the formation of ROS and activates
several destructive biochemical processes, determining excitatory
damage and neuronal degeneration (Ilieva et al., 2009; Vucic
et al., 2014). Therefore, the rapid removal of glutamate is required
to prevent neuronal toxicity. In particular, the isoform 2 of the
astroglial glutamate transporter (EAAT2) is involved in keeping
the amount of glutamate below excitotoxic level in the nervous
system.
Before the identification of the genetic links of fALS,
glutamate excitotoxicity was one of the first hypotheses proposed
as pathogenetic mechanism of ALS (Bendotti and Carrì,
2004). The motor cortex and spinal cord of ALS patients and
transgenic mutant SOD1 mouse models were found to have
reduced EAAT2 level, probably due to the presence of aberrant
EAAT2 mRNA or to cleavage of the EAAT2 transporter.
This leads to an increase of synaptic glutamate concentration
and an over-stimulation of glutamate postsynaptic receptors,
determining excitotoxic neuronal degeneration (Lin et al., 1998;
Zarei et al., 2015). The loss of functional EAAT2 was also
observed in affected brain regions of other neurodegenerative
diseases, such as Alzheimer’s and Huntington’s diseases
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(Guo et al., 2003). To establish whether loss of functional
EAAT2 in ALS was a primary cause of neuron degeneration or
a consequence of cell damage, transgenic mutant SOD1 mice
overexpressing EAAT2 (EAAT2/G93A double transgenic mice)
were generated to investigate whether supplementation of
EAAT2 loss would delay or rescue the disease. Mice with an
increased EAAT2 expression showed a delay in motoneuron
degeneration and disease progression. Since no change in
lifespan was found comparing EAAT2/G93A mice with
SOD1(G93A) mice, it was concluded that loss of EAAT2 may
contribute to motoneuron degeneration in ALS but is not the
principal cause (Guo et al., 2003).
Moreover, the selective vulnerability of motoneurons in ALS
may be due to a higher permeability to calcium of these cells
compared with other neurons, probably caused by a defect in
RNA editing of the GluR2 subunit of AMPA, which renders this
receptor more permeable to calcium (Kawahara et al., 2004).
Oxidative Stress
Free radicals or ROS are natural products of oxygen metabolism.
The term oxidative stress is used when the production of ROS
is higher than the capacity of cells to remove them. This leads
to the accumulation of ROS, which causes irreversible damage
to cell structures and macromolecules, such as proteins, DNA
and RNA.
SOD1 is the major enzyme to prevent oxidative damage and to
reduce superoxide leakage from mitochondria. Mutations in this
gene can cause alterations in the activity of the protein leading to
cytotoxicity.
Early studies suggested that mutations in the SOD1 gene
cause a complete loss of protein function (Deng et al., 1993).
Subsequently, in vitro experiments demonstrated that mutant
human SOD1 proteins (such as the G37R mutation) are active
and stable, promoting neural apoptosis in a dominant manner
(Borchelt et al., 1994; Rabizadeh et al., 1995). These studies
suggest ALS pathogenesis may involve not only a decrease/loss
in the enzymatic function of SOD1, but is also probably due
to a dominant toxic gain of function of the enzyme. It has
been proposed that mutant SOD1 could revert its normal
antioxidant activity producing toxic superoxide: the mutated
protein could take electrons from other cellular antioxidants and
donate them to molecular oxygen, producing superoxide and
making SOD1 the source of oxidative stress (Beckman et al.,
2001; Liochev and Fridovich, 2003). Increased levels of free
radicals and of oxidative damage were found in cerebrospinal
fluid (CSF), serum and urine samples of ALS patients (Zarei
et al., 2015) and could be due to an altered geometry in the
active site of the mutated SOD1, which allows entry of reducing
substrates.
Oxidative stress in ALS may also derive from a defective
oxidative phosphorylation (Bacman et al., 2006), as reported
from studies of CSF in transgenic mice and in patients, in which
ROS produced from defective oxidative phosphorylation, such as
3-nitrotyrosine, were found in high concentration (Tohgi et al.,
1999). Moreover, this study combined the increase of ROS with
mitochondrial dysfunction and provided an example of how
different pathogenetic mechanisms of ALS may be inter-related.
Protein Aggregates
Protein aggregates are a pathological hallmark of many
neurodegenerative diseases such as Alzheimer’s, Parkinson’s,
Huntington’s diseases and ALS. These aggregates derive from
the accumulation of misfolded proteins, which oligomerize and
aggregate, gaining toxic properties (Julien, 2001). Inclusions rich
in mutated SOD1 proteins have been found in tissues from both
sALS and fALS cases, as well in mutant SOD1 transgenic mice
(Boillée et al., 2006a).
The structure of SOD1 in the aggregates is not clear, but
it seems that the protein is disulfide-reduced and lacks both
copper and zinc atoms. The aberrant accumulation of mutated
proteins is also related to a lack of their degradation, resulting
in aggregates consisting of mutated SOD1 and other mutated
proteins related to ALS, such as TDP43 or FUS.
TDP43, an RNA-binding protein, is normally located in the
nucleus, where it regulates transcription, splicing and mRNA
transport. This protein is necessary for the prevention of DNA
damage (Hill et al., 2016). TDP43 aberrant protein inclusions
have been reported in 80% of ALS cases and it seems that the
cytoplasmic accumulation is due to mutations in the 3′ UTR
region of the genes, which lead to overexpression and altered
location of the protein (Neumann et al., 2006; Coan and Mitchell,
2015). As TDP43, FUS is a nuclear protein. The accumulation of
TDP43 and FUS in the cytoplasm is probably due to mutations
which prevent their shuttles to the nucleus (Dormann and Haass,
2011).
Protein inclusions in ALS contain also other components,
such as chaperones, mitochondrial proteins, ubiquitin and
neurofilaments (NFs). Moreover, the aberrant accumulation of
ubiquitin and of ubiquinated and misfolded proteins could affect
the normal function of the proteasome machinery, impairing
normal protein degradation and leading to further protein
accumulation, degeneration and death of motoneurons.
Accumulation of Neurofilaments
Accumulation and/or aggregation of NFs in the cell bodies and
axons, and abnormal location of phosphorylated NFs in the cell
body are typical pathological hallmarks of ALS. NFs are the major
intermediate filaments in neurons; they are the most abundant
cytoskeletal components of large myelinated axons and control
the axonal caliber. NFs are formed by the co-polymerization of
light (NF-L, 65 kDa), medium (NF-M, 95 kDa) and heavy (NF-H,
115 kDa) subunits. NF-L is necessary for filament assembly,
whereas NF-M and NF-H form links with other NFs in the axon
(Julien, 1999). Also α-internexin is an integral component of NFs
in the CNS, in particular during axon elongation (Yuan et al.,
2006).
The mechanisms leading to the formation of NF aggregates in
ALS are still unclear. Mutations in NF genes occur in fALS and
sALS and seem to be correlated with abnormal phosphorylation
of NFs. Phosphorylation of NF-H and NF-M usually occurs only
in the axon and the rate of NF transport is inversely correlated
to their phosphorylation state. The abnormal phosphorylation
could alter the axonal transport of NFs, determining their
accumulation in the cell bodies and proximal axon. This
accumulation could be at the basis of defects in axonal transport
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of other cellular components important for cell survival, such as
mitochondria (Xiao et al., 2006).
The aggregation of NFs could also be due to their altered
stoichiometry: overexpression or downregulation of NF subunits
in murine models of ALS provoke NF accumulation (Perrot and
Eyer, 2009). Transgenic SOD1(G93A) mice which overexpress
the NF-L subunit exhibit excessive accumulation of NFs in the
perikarya and proximal axon of motoneurons in the ventral
horn of the spinal cord, accompanied by proximal axonal
swelling and subsequent degeneration (Xu et al., 1993). In situ
hybridization revealed a consistent reduction in NF-L mRNA
levels in degenerating spinal motoneurons of ALS patients
(Tomkins et al., 1998; Al-Chalabi et al., 1999; Wong et al., 2000),
while NF-L deficiency accelerates motoneuron degeneration in
transgenic mice (Xu et al., 1993), indicating the importance of
NF protein stoichiometry in the distribution and aggregation
of NFs.
Surprisingly, overexpression of both NF-L and NF-H subunits
significantly slowed down disease progression in mouse models
of ALS. Double transgenic mice (SOD1(G93A) gene and NF-L or
NF-H genes) showed a significant delay in disease progression
and an extension of survival compared with SOD1(G93A)
mice (Kong and Xu, 2000), suggesting a protective effect
of NF accumulation. The mechanism of this protection is
unclear, but perikaryal accumulation of NFs rather than their
axonal deficiency could be responsible in slowing down the
disease.
The abnormal organization of NF seems to be involved in
the pathogenesis of ALS, although the relationship between
their accumulation and motoneuron neurodegeneration remains
unclear. Despite the correlation of some mutations of NF genes
with ALS disease, specific mutations in NF genes have not been
identified, indicating that probably NF gene mutations are not
a common cause of ALS but could represent a risk factor for
selective motoneuron vulnerability.
Neuroinflammation
A common characteristic of ALS and other neurodegenerative
diseases is the neuroinflammatory response, characterized by
activated microglia, astrogliosis and infiltrating immune cells
in the sites of neuronal injury. Although ALS involves the
selective death of motoneurons, different lines of evidence have
shown that neuronal injury is non-cell-autonomous but depends
on a finely regulated dialog between motoneurons and glial
cells. Deregulated communication between neurons and glial
cells compromises neuronal homeostasis and survival, and the
involvement of mutant glia in motoneuron degeneration is well
documented. The expression of mutant SOD1 gene limited to
motoneurons is not sufficient to cause disease in transgenic
mouse model of ALS, leading to suppose that their degeneration
requires the participation of non-neuronal cells (Clement et al.,
2003). Non-mutated motoneurons surrounded by glial cells
carrying a SOD1 mutated gene develop the pathological
phenotype, while mutated motoneurons surrounded by
wild-type glia show a healthy phenotype (Clement et al.,
2003). Moreover, the replacement of mutant SOD1 in glial cells
with wild-type glia delays the disease and prolongs the survival
of ALS mice (Lee et al., 2012). Thus, damaged glia and neurons
act together contributing to the process of neurodegeneration
and to disease progression.
In the CNS, microglial cells are the resident macrophages
and represent the first line of defense against infection
or injury, monitoring the extracellular environment and
interacting with neurons and astrocytes. These cells have
immunological properties, with both neuroprotective and
neurotoxic potential. After CNS injury, microglial activation
is a major component of neuroinflammation. In particular,
in ALS the interaction between motoneurons and microglia
initially protects neurons. When motoneuron damage worsens,
motoneurons and astrocytes release misfolded proteins (such
as mutated SOD1) and other toxic molecules that stimulate
the activation of microglial cells, which switch from an
anti-inflammatory and neuroprotective to a pro-inflammatory
and neurotoxic phenotype (Appel et al., 2011; Zhao et al.,
2013). Microglial activation includes activated microglia (M1)
and alternatively activated microglia (M2). M1 microglia are
cytotoxic and secrete ROS, proinflammatory cytokines and
neurotoxic molecules, mediating motoneuron death (Almer
et al., 1999; Elliott, 2001). Studies in SOD1 transgenic mice
have shown that the replacement of mutant SOD1 microglia
with wild-type microglia, as well as the specific reduction
of the expression of mutant SOD1 gene in these cells,
significantly reduce motoneuron degeneration and extend
the lifespan of the animals (Beers et al., 2006; Boillée
et al., 2006b). This points to an involvement of microglial
cells in neurodegeneration, underlining that mutant
SOD1 microglia acquire a M1 toxic phenotype promoting
disease progression.
Unlike the M1 phenotype, M2 microglia produce high
levels of anti-inflammatory cytokines and neurotrophic factors
that enhance the protection and survival of motoneurons.
The upregulation of M2 markers in the spinal cord of
SOD1(G93A) mice demonstrated that in the early stage of the
disease microglia display an M2 phenotype which promotes
repair and regeneration. During disease progression, damaged
motoneurons induce microglial cells to release ROS and
proinflammatory cytokines and to acquire an M1 phenotype
leading to further neurotoxicity (Zhao et al., 2013). Activated
microglia increase during disease progression due to their
interaction with the cell microenvironment at different stages
of the disease, which plays a key role in determining a
neuroprotective or neurotoxic function of microglia.
Astrocytes are the largest glial cell components of the
CNS and play many important functions in maintaining and
supporting neurons. Reactive astrogliosis has been implicated
in neurodegeneration and in the progression of ALS. One
of the most important functions of astrocytes in supporting
neurons is to maintain low concentration of glutamate in the
synaptic cleft through EAAT2 glutamate receptors. In patients
with sALS and fALS, as well as in SOD1 mice, astrocytes
downregulate the EAAT2 transporter, determining a less
efficient uptake of glutamate and contributing to excitotoxicity
(Howland et al., 2002). Other studies have shown that, upon
activation, an insufficient release of neurotrophic factors and
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the release of neurotoxic factors from astrocytes are involved
in neurodegeneration (Komine and Yamanaka, 2015). This
was also indicated by analyses of astrocytes in post-mortem
tissue of ALS patients, which revealed an upregulation of
22 genes encoding chemokines, proinflammatory cytokines and
components of the complement cascade, which could exacerbate
neural damage and loss of already compromised neurons (Zhao
et al., 2013). Moreover, the selective removal of the mutant
SOD1 gene from astrocytes, or the transplantation of healthy
astroglial cells, slowed down the disease progression, attenuated
motoneuron loss and increased the lifespan in SOD1 transgenic
mice (Lepore et al., 2008; Yamanaka et al., 2008), indicating
the involvement of astroglial cells in the neurodegeneration
process.
THERAPEUTIC APPROACHES IN ALS
Given the complexity of ALS pathogenesis, to date there is no
effective treatment to cure or significantly ameliorate the quality
of life of patients. Nevertheless, several therapeutic strategies
have been proposed to relieve symptoms and improve the quality
of life of ALS patients.
Pharmacological Therapy
The only drug approved by the US Food and Drug
Administration is riluzole (2-amino-6-trifluoromethoxy
benzothiazole, also known as rilutek), that acts as an inhibitor
of glutamate release from the presynaptic terminals by blocking
voltage-gated sodium channels, thus limiting glutamate
excitotoxicity. Moreover, riluzole has other neuroprotective
pharmacological actions, including the modulation of the
NMDA ionotropic receptors, inactivation of voltage-dependent
sodium channels and inhibition of the uptake of the inhibitory
neurotransmitter γ–aminobutyric acid (Gurney et al., 1998).
In vitro studies have demonstrated that riluzole protects
motoneuron cell lines from glutamate stress, blocking excitotoxic
damage (Doble, 1997). Neuroprotection has also been observed
in vivo in models of ALS, in which treatment with the drug
before the onset prolongs survival and slows neurodegeneration,
improving motor performance of the treated animals (Gurney
et al., 1998). However, the clinical use of riluzole (100 mg
daily) prolongs the life of patients by 3 months, although the
results obtained in clinical trials are often controversial (Miller
et al., 2012). The beneficial effect is very modest: only a small
beneficial effect in both bulbar and limb functions but no
effect on muscle strength were found (Musarò, 2013). In some
studies, the neuroprotective effect of riluzole was examined in
combination with other drugs. Rasagiline is an antiapoptotic
drug which reduces oxidative stress (by inhibition of monoamine
oxidase B) and preserves mitochondrial membrane potential.
The combined treatment of rasagiline with riluzole determined
a dose-dependent improvement in motor performance and
extended survival in SOD1(G93A) mice more than treatments
in which rasaligine was administered alone (Waibel et al., 2004).
Given the modest efficacy and the high cost, doubts persist about
the clinical administration of these drugs and additional studies
are needed to improve their clinical effect.
Since loss of neurotrophic support to motoneurons has
been proposed as mechanism contributing to ALS, several
studies have reported that increased levels of growth factors
(such as insulin-like growth factor 1, glial cell line derived
growth factor and ciliary neurotrophic factors) have a positive
effect in experimental models of the disease (Gould and
Oppenheim, 2011), promoting neuron hypertrophy and survival.
In particular, in animal models, the efficacy of growth factors
delivered by viral-mediated gene (to stimulate the secretion of
specific trophic factors to target cells) or by directed infusion of
the trophic factors in the spinal cord or in the brain provided a
modest benefit slowing down disease progression and increasing
survival of the animals (Boillée et al., 2006a). However, human
trials based on the use of neurotrophic factors showed modest or
no effects (Beghi et al., 2011).
These pharmacological strategies are directed against one or
a few altered mechanisms involved in ALS and their use has
only a minimal impact on the disease course. Probably, for an
efficient therapeutic approach it could be helpful to counteract
different pathogenetic mechanisms involved in the disease. For
this reason, since the transplantation of stem cells and gene
therapy can act via multiple mechanisms, in the last years
an increasing interest has been addressed to these therapeutic
approaches.
Gene Therapy
ALS can be caused by dominant mutations in SOD1 that give
toxic property to the mutant protein. Since the complete absence
of the SOD1 gene does not cause the disease in mice (Reaume
et al., 1996), the SOD1 gene silencing has been regarded as an
interesting possibility to limit the course of the pathology. In
particular, a lentivirus encoding for a RNA silencing (siRNA)
that catalyzes the selective degradation of SOD1-mRNA was
used in this approach. The injection of this virus in the muscle
or directly in the spinal cord of transgenic mouse models of
ALS reduced SOD1 expression delaying the neurodegeneration,
but data about the slowing down of the disease progression
and survival are controversial (Ralph et al., 2005; Raoul et al.,
2005). Moreover, this approach could be used only for a familial
form of ALS and not for sALS which represents the majority of
cases.
An antisense oligonucleotide directed to SOD1-mRNA was
found to decrease the concentration of SOD1 mRNA and
related protein in the spinal cord, prolonging survival in the
SOD1(G93A) rat model of the disease (Smith et al., 2006). After
this encouraging result, to date the only clinical trial performed
in phase I has shown the safety, tolerability and pharmacokinetics
of this antisense oligonucleotide (Miller et al., 2013). Despite the
small number of patients, the study showed that the intrathecal
administration of antisense oligonucleotide is safe and well-
tolerated. However, antisense oligonucleotides do not cross the
blood-brain barrier (BBB) and, to cure ALS patients, they should
be delivered directly to the CNS (O’Connor and Boulis, 2015),
which is difficult to achieve. Moreover, this type of treatment
requires a constant infusion of repeated doses of the antisense
nucleotide. Gene therapy requires to be optimized for a successful
approach to neurodegenerative diseases.
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Stem Cell Therapy
Stem cells are becoming a promising therapeutic approach to
neuronal replacement and regeneration, becoming a source of
great hope and expectation for patients affected by different
neurodegenerative diseases, including ALS. The use of stem cells
as therapeutic approach is of great interest given their ability to
home to damaged sites, stimulate tissue repair and regeneration,
and direct their differentiation in response to extracellular signals
(Faravelli et al., 2014).
Stem cells are a group of cells with the ability of self-renewal
and to differentiate in many cell types. They are usually divided
in two major subtypes: embryonic stem cells (ESC), originated
from the inner cell mass of blastocyst and that possess the
ability to produce all the three germ layers; adult stem cells,
specialized cells that can differentiate into many cell types of
different organs, usually determined by the germ layer of origin
(Meamar et al., 2013). Among the different stem cell types,
the most common used for neurological diseases are: ESC,
neural stem cells (NSC), MSC and induced pluripotent stem
cells (iPSC). The best source of stem cells should be chosen
on the basis of their biological features to survive, migrate to
the damaged tissues, engraft and differentiate (Faravelli et al.,
2014).
The main objectives of the treatment with stem cells are
cellular replacement and neural protection. The first objective
would be achieved by the stem cell differentiation into specific
cell subtypes involved in the disease, with the purpose to
replace dead cells. The second objective involves the use of
stem cells based on their ability to release trophic factors and
to remove neurotoxic molecules, providing a local support in
the microenvironment of the damaged area, acting as neural
protectors.
Among the different types of stem cells used in the treatment
of neurodegenerative diseases, MSC seem to have aroused the
highest interest as promising candidates (Baglio et al., 2012).
MSC can be isolated from a variety of fetal and adult tissues, such
as skeletal muscle, placenta, umbilical cord, blood and adipose
tissue. Adipose tissue is gaining increasing interest because it is
available in large amount from liposuction, allowing autologous
transplantation of adipose-derived MSC (ASC).
There are several technical advantages in the application of
MSC. First of all, their isolation is safe and easy, their expansion
in vitro is simple and it was demonstrated, both in vitro and
in vivo, that they can differentiate in neural-like, glial-like and
astrocytic-like cells (Marconi et al., 2013; Haidet-Phillips and
Maragakis, 2015). MSC are less susceptible to tumoral changes
and do not require immunosuppressive treatment to prevent
rejection given the possibility of autologous transplantation.
Moreover, as the other stem cells, after transplantation and
migration, MSC are attracted to the damaged area, where they
increase the release of neurotrophic factors (Meamar et al., 2013).
Several studies have provided evidence for the efficacy of MSC
in in vivo models of ALS, demonstrating that their injections
can delay the death of motoneurons, decrease the inflammatory
response and may prolong survival of the animals. Results of
some preclinical studies in in vivo models of ALS with MSC are
reported in Table 1.
Due to the positive results obtained in in vivo models of the
disease, in the last years numerous cell-based clinical trials for
ALS have used MSC, and have reported the feasibility, safety and
TABLE 1 | Applications of mesenchymal stem cells (MSC) in amyotrophic lateral sclerosis (ALS) models.
ALS model Stem cell type Injection specifics Results References
SOD1(G93A)
mouse
hBM-MSC Intraspinal (105 cells)
Presymptomatic (week 28)
Improvement of motor performance, migration and
engraftment of MSC in the spinal cord, prevention of
astroglial and microglial activation
Vercelli et al. (2008)
SOD1(G93A)
rat
rHSC Intrathecal (2 × 106 cells)
Clinical onset (week 12)
Reduction of motoneurons death and inflammation,
improvement of motor functions and extended survival
Boucherie et al. (2009)
SOD1(G93A)
mouse
hBM-MSC Intrathecal (106 cells)
Presymptomatic (week 8)
Improvement of motor performance, reduction of
motoneuron death and prolonged lifespan
Kim et al. (2010)
SOD1(G93A)
rat
rMSC Intraspinal (105 cells) and
intravenous (2 × 106 cells)
Clinical onset (week 16)
Improvement of motor performance, increase of survival,
migration and engraftment of MSC in the spinal cord
Forostyak et al. (2011)
SOD1(G93A)
mouse
hBM-MSC transfected
with GLP-1
Intracerebroventricular
(2.8 × 103 cells)
Presymptomatic (week 5)
Improvement of motor performance, delay of disease onset
and survival
Knippenberg et al. (2012)
SOD1(G93A)
mouse
mBM-MSC Intravenous (3 × 106 cells)
Clinical onset (week 12)
Improvement of motor functions and survival. Reduction of
oxidative stress; limited migration and engraftment of MSC
in the spinal cord
Uccelli et al. (2012)
SOD1(G93A)
mouse
mASC Intravenous (2 × 106 cells)
Clinical onset (week 11)
Improvement of motor functions, delay of motoneuron
death, limited migration and engraftment of MSC in the
spinal cord, modulation of neurotrophic molecules.
Marconi et al. (2013)
SOD1(G93A)
mouse
hBM-MSC Intracisternal (3 × 105 cells)
Clinical onset (week 16–18)
Delay of motoneuron death, reduction of astrogliosis,
modulation of microglial activation, increase of IL-13
expression
Boido et al. (2014)
Abbreviation: hBM-MSC, human bone marrow mesenchymal stem cells; rHSC, rat hematopoietic stem cells; mBM-MSC, murine bone marrow mesenchymal stem cells;
mASC, murine adipose-derived MSC.
Frontiers in Cellular Neuroscience | www.frontiersin.org 8 March 2017 | Volume 11 | Article 80
Bonafede and Mariotti ALS: Pathogenesis and New Therapeutic Approaches
TABLE 2 | Clinical applications of MSCs in ALS patients.
Stem cell type and
specifics
Delivery method/Cell number Trial status and details References
Autologous BM-MSC Intraspinal (14–60 × 106 cells) The approach is safe and feasible. Some patients
demonstrate electroneuromyography improvements
Deda et al. (2009)
Autologous BM-MSC Intrathecal (54.7 × 106 ± 17.4 × 106 cells)
Intravenous (23.4 ± 6 × 106 cells)
The approach is safe, feasible and induces immediate
immunomodulatory effects. Phase I complete, Phase II open
to evaluate preliminary effects at various doses of cells
Karussis et al. (2010)
Autologous BM-MSC Intraspinal (15–110 × 106 cells) The approach is safe and feasible, with no signs of toxicity,
adverse events or abnormal cell growth. Phase I complete; no
long-term harmful consequences, however disease
progression did not appear to be slowed
Mazzini et al. (2010,
2012)
Autologous BM-MSC Intraspinal (138–602.87 × 106 cells) The approach is safe and feasible. No acceleration in decline
noted and an increase in spinal cord motoneurons numbers
were identify after autopsy
Blanquer et al. (2012)
Autologous BM-MSC Intraventricular (1 × 106 cells/kg) The approach is safe and feasible Baek et al. (2012)
Autologous BM-MSC Motor cortex (2.5–7.5 × 105 cells) The approach is safe and feasible, with a higher significant
survival in treated patients
Martinez et al. (2009),
Martínez et al. (2012)
Autologous BM-MSC and
neural-induced MSC
Intravenous (42–102 × 106 cells) and
intralumbar (5–9.7 × 102 × 106 cells)
The approach is safe and delay the disease progression,
improving the quality of life of patients
Rushkevich et al. (2015)
Autologous BM-MSC Intrathecal (1–2 × 106 cells)
Intramuscular (1–48 × 106 cells)
The approach is safe and feasible. Phase I complete, Phase II
open to evaluate preliminary effects at various doses of cells
Petrou et al. (2016)
Abbreviation: BM-MSC, bone marrow mesenchymal stem cells.
immunological effects of administration of MSC to ALS patients
(Table 2).
However, despite stem cell-mediated therapy represents a new
promising approach to cure ALS and other neurodegenerative
disorders, to date no significant effects on the disease progression
have been obtained compared to placebo-treated controls and
key issues need to be solved before extensive clinical translation.
First, it is necessary to identify the delivery of the cells to the
CNS using standardized protocols and considering the route of
administration, the dose of cells, the timing and the number of
cell-injections. Moreover, given the high proliferative capacity
of stem cells, the oncogenic transformation of transplanted
cells should be prevented and their immunorejection
avoided.
After the demonstration that only a small proportion of
injected stem cells can reach, engraft and differentiate in the
site of injury, the idea that the beneficial effect of stem cells is
indirect and most probably depends on their paracrine activity
is becoming more pervasive (Baglio et al., 2012; Maumus et al.,
2013; Lai et al., 2015). Stem cells produce a large spectrum of EVs
which contain cytokines, chemokines, growth factors, proteins
and nucleic acids, and can exert significant effects on cells,
mediating cell-cell communication. These observations led to the
hypothesis that stem cells exert their beneficial effect through
the secretion of EVs which enhance the repair of the damaged
area releasing their content. Thus, EVs could be used as a novel
cell-free therapeutic approach, avoiding all the risks associated
with the use of cells.
EXTRACELLULAR VESICLES
Intercellular communication plays a fundamental role in
multicellular organisms. It can be mediated through a direct
contact between cells or by the secretion of molecules, such
as growth factors, chemokines and cytokines, exerting their
effect on cells in their proximity. In the last decades, a
novel mechanism of cell communication has been proposed
and involves intercellular transfer of EVs. These vesicles
represent a vehicle to transfer membrane and cytoplasmic
proteins, lipids and nucleic acids between cells, becoming
an integral part of the intercellular microenvironment
and playing a role in many physiological and pathological
processes.
EVs are spherical particles enclosed by a phospholipid
bilayer. They can be distinguished on the basis of their size
(ranging from 30 nm to 1000 nm in diameter), lipid and
protein composition, sedimentation rate, flotation density on a
sucrose cargo and biogenesis pathway (Maumus et al., 2013; Lai
et al., 2015). According to the biogenesis, morphology, protein
compositions and size, EVs are classified as microvesicles and
exosomes.
Microvesicles
Microvesicles (also known as shedding vesicles) range from
150 nm to 1000 nm in diameter, although the size ranges
of microvesicles and exosomes may overlap, especially when
vesicles are isolated from biological fluids (György et al.,
2011). Microvesicles are released by budding from the plasma
membrane through a process dependent on intracellular
calcium concentration, calpain and cytoskeleton reorganization,
unlike exosomes, whose release is independent of cell calcium
influx (Maumus et al., 2013). Calcium ions are responsible
for the changes in phospholipid distribution in the plasma
membrane, which is of primary importance for the formation
of cytoplasmic protrusions (Biancone et al., 2012). Microvesicles
are surrounded by a phospholipid bilayer and contain proteins,
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lipids and nucleic acids depending on the cell of origin.
A typical characteristic of these vesicles is that they usually
contain proteins associated with lipid rafts and cholesterol,
sphingomyelin, ceramide and phosphatidylserine (Biancone
et al., 2012).
Exosomes
Exosomes are EVs produced by almost all cell types, with
a diameter ranging from 30 nm to 100 nm and a flotation
density of 1.10–1.18 g/ml (Lai et al., 2015). They are
present in many biological fluids, including urine, saliva,
blood, amniotic fluid and CSF, as well as in a conditioned
medium of cell culture (Kourembanas, 2015). The most
commonly used techniques for their isolation are represented
by ultracentrifugation, ultrafiltration and immunoprecipitation,
although many isolation kits are currently available (Maumus
et al., 2013; Raposo and Stoorvogel, 2013).
The morphology of exosomes is described as ‘‘cup shaped’’
after visualization by transmission electron microscopy. They
are surrounded by a phospholipid bilayer and contain many
characteristic proteins, lipids and functional RNAs, in particular
mRNAs and microRNA (miRNAs) that can be transferred
between cells. Concerning protein composition, exosomes from
different cell types present typical endosome-associated proteins
(as GTPase and Alix) or membrane proteins (as tetraspanin
CD63, CD9, CD81 and heat-shock proteins Hsp70 and Hsp90)
involved in their biogenesis, transport and fusion (Raposo and
Stoorvogel, 2013).
The cargo and composition of exosomes are unique and
depend in part from the cell of origin and its physiological
state (Jarmalavi cˇiu¯te˙ and Pivoriu¯nas, 2016). Exosomes derived
from diseased cells are usually implicated in the spread
of pathological processes or in the propagation of diseases,
while exosomes derived from stem cells can be used as
therapeutic tools (Jarmalavi cˇiu¯te˙ and Pivoriu¯nas, 2016). Many
studies on the biochemical composition of exosomes have
been performed. The results on the composition of exosomes
in terms of proteins, nucleic acids and lipids are reported
in the database ExoCarta1, recently incorporated in another
database, Vesiclepedia, which includes data from all types
of EVs (Mathivanan et al., 2012; Raposo and Stoorvogel,
2013).
Some of the properties (such as size and morphology) of
exosomes overlap with those of microvesicles, but exosomes are
the only class known to have an endosomal origin, distinguishing
them from other vesicles. Exosomes originate from invagination
and endocytosis of the plasma membrane. These early
endosomes mature through a series of transformation and
changes in protein content to become late endosomes. The
membranes of late endosomes give rise to vesicles ranging from
30 to100 nm in size (exosomes), contained in multivesicular
bodies which during this phase have incorporated proteins
(from plasma membrane and Golgi complex), lipids and
nucleic acids (Zhang et al., 2016). The multivesicular bodies
can be degraded in lysosomes or can be fused with the
1http://www.exocarta.org
plasma membrane, releasing exosomes in the extracellular
environment.
Released exosomes can act in a paracrine or endocrine
manner, modifying the behavior of adjacent or distant cells.
The role of exosomes in physiological and pathological processes
depends on their ability to interact with recipient cells to deliver
their content. In particular, the vesicles can be internalized by
recipient cells by endocytosis, by fusion or after contact with
surface receptors (Raposo and Stoorvogel, 2013; Kourembanas,
2015).
Functions of Extracellular Vesicles
in Intercellular Communication
Once secreted from the cells, exosomes and microvesicles can
interact with adjacent or distant recipient cells and deliver
their cargo, modulating their activities. In addition to providing
biologically active molecules, EVs protect these molecules against
degradation until they reach the target site, and facilitate their
uptake from the recipient cells. The uptake can be direct,
by fusion with the target cell or by endocytosis, or indirect,
mediated by receptor binding. The fusion of EVs with the
plasma membrane determines the direct release of the content
of EVs inside the cells, while, with the other mechanisms,
EVs remain within the endosome until they fuse with the
endosome membrane, releasing their content into the cytoplasm.
Alternatively, endosomes can fuse with lysosomes, leading to the
degradation of the vesicles and their content (Turturici et al.,
2014).
The proteins and functional RNAs contained in the EVs
are implicated in many biochemical and cellular processes,
such as communication, inflammation, tissue repair and
regeneration, cell differentiation, as well as metabolism (Lai et al.,
2015).
The cargo, and therefore the functions, of EVs depend on
the phenotype of the cell of origin. Nevertheless, it has been
shown that a selective enrichment of specific molecules occurs:
some proteins and, above all, functional RNAs are preferentially
sorted to EVs and released through them (Li et al., 2013) and the
selective fate of molecules into the EVs is finely regulated in both
physiological and pathological conditions. During development,
secreted EVs contain morphogens (such as sonic hedgehog
and retinoic acid), playing an important role in developmental
signaling and morphogenesis (Greco et al., 2001). EVs also
contain bioactive lipids that can stimulate cytokine secretion,
induce chemotaxis or inhibit apoptosis (Turturici et al., 2014).
EVs released from tumor cells contain molecules which stimulate
proliferation, angiogenesis and metastasis (Turturici et al., 2014).
Moreover, in this case, cells release EVs containing caspase-3 and
Fas ligand, allowing tumor cells to escape from apoptosis and
immunosurveillance.
Concerning EVs secreted from stem cells, it was hypothesized
that they can be involved in self-renewal and the pluripotency
typical of these cells, and that they can play key roles in signaling
within the stem cell niche.
Recently, more attention has been given to the ability of
EVs to transfer genetic information between cells, in particular
Frontiers in Cellular Neuroscience | www.frontiersin.org 10 March 2017 | Volume 11 | Article 80
Bonafede and Mariotti ALS: Pathogenesis and New Therapeutic Approaches
mRNAs and miRNAs. Intercellular communication based on
these functional RNAs require the selectively compartmentation
of RNAs in an appropriate vehicle, the protection from
circulating RNAses, and the ability of RNA to retain the
capability to control gene expression. For these reasons, EVs
represent an optimal candidate for genetic exchange between
cells, modulating the behavior of recipient cells. Exosomes
released from MSC may regulate neurite outgrowth and
neural plasticity by the transfer of miRNA-133b (Xin et al.,
2012). Exosomes obtained from bone marrow-MSC (BM-MSC)
contain miRNA-21 and miRNA-222 which are involved in cell
proliferation and differentiation (Collino et al., 2010). This
indicates that the biological effects on the neighboring cells can
be, in part, regulated by shuttled-RNA of EVs.
Therapeutic Applications of Exosomes
Since exosomes and microvesicles can transfer biological
information over long distance, increasing attention has been
paid to these vesicles as promoters of suppressors of pathological
processes. As exosomes are smaller than microvesicles and
capable to cross the BBB, here we will focus on the use of
exosomes as a potential therapeutic tool in neurodegenerative
diseases, such as ALS, Alzheimer’s and Parkinson’s diseases.
There is evidence that infusion of exosomes isolated from
neuroblastoma or primary neurons into the brain ameliorates
Alzheimer’s disease course in a mouse model, sequestering
intracerebral amyloid-β (Aβ) peptide (Yuyama et al., 2015).
Another cellular source to obtain exosomes is represented by
MSC and several studies have demonstrated the neuroprotective
effects of these exosomes. In particular, exosomes derived
from MSC isolated from dental pulp protected dopaminergic
neurons against neurodegeneration induced by 6-hydroxy-
dopamine oxidative stress, reducing the production of ROS and
consequently apoptosis, indicating a potential therapeutic use of
exosomes in the treatment of Parkinson’s disease (Jarmalavi cˇiu¯t
et al., 2015). Another study reported that exosomes isolated from
adipose tissue-MSC decrease the levels of Aβ in an in vitro model
of Alzheimer’s disease, thanks to the high level of neprilysin
(an important protein for the proteolysis of Aβ, whose activity
and expression decrease during the disease) contained in the
exosomes (Katsuda et al., 2013). The neuroprotective effect of
exosomes obtained from ASC was also demonstrated in human
neuroblastoma cell line and primary murine hippocampal
neurons after an oxidative insult (Farinazzo et al., 2015).
Moreover, exosomes derived from BM-MSC have been used
to improve recovery and neuroregeneration after stroke and
traumatic brain injury (Xin et al., 2013; Zhang et al., 2015).
We recently demonstrated that exosomes isolated from
ASC exert a neuroprotective effect in an in vitro model
of ALS (Bonafede et al., 2016). In this study, we used
the motoneuron-like cell line NSC-34 transiently and stable
transfected with different SOD1 point mutations to mimic the
behavior of ALS motoneurons, and H2O2 as pathological insult.
The presence of exosomes increased ALS motoneuron survival,
probably counteracting the apoptosis pathway, underlining
their possible therapeutic application to ALS. Another study
demonstrated the possible application of ASC derived exosomes
in ALS, reducing mutant SOD1 aggregation and restoring
mitochondrial protein function (Lee et al., 2016a). Moreover,
exosomes derived from ASC ameliorated the disease progression
in an in vitro model of Huntington’s disease, reducing huntingtin
protein aggregates and the level of apoptotic proteins (Lee et al.,
2016b). Altogether, these studies indicate a protective beneficial
role of exosomes in different neurodegenerative diseases.
Increasing evidence suggests that exosomes display
anti-inflammatory properties, reducing the number of activated
inflammatory microglial cells, supporting oligodendrocytes
and protecting neurons (Zhuang et al., 2011; Pusic et al., 2014).
Moreover, exosomes injected intranasally are transported rapidly
to the brain, where they can be taken up by microglial cells
(Zhuang et al., 2011). Since, as stated above, neuroinflammation
is a common feature of neurodegenerative diseases, the
suppression of the neuroinflammatory response and the
possibility to reach easily the CNS are of great importance for
the treatment of these pathologies.
The increasing attention to the use of exosomes for the
treatment of neurodegenerative diseases derives from the
capability of exosomes to cross the BBB, the physiological
barrier that separates the brain parenchyma from circulating
blood in the CNS. As mentioned before, current treatments
for neurodegenerative diseases are often symptomatic and do
not halt the degenerative processes; the main problem for the
cure of these pathologies is the inability of cells and drugs to
cross the BBB. Recent studies have reported that exosomes,
unlike microvesicles, can cross the BBB: the hypothesis is that
exosomes are internalized by endothelial cells and, through the
release of specific cargo, they affect the integrity of cell junctions
increasing permeability between cells and allowing a massive
entry of vesicles in the CNS (Zhou et al., 2014; Tominaga et al.,
2015; Jarmalavi cˇiu¯te˙ and Pivoriu¯nas, 2016), where they could
exert neuroprotective actions (Figure 2).
In this regards, we recently set up a protocol to label exosomes
with superparamagnetic iron oxide nanoparticles, and the use
of labeled exosomes, which allows their detection by magnetic
resonance imaging, could be useful to verify this hypothesis
(Busato et al., 2016).
CONCLUSIONS AND FUTURE
PERSPECTIVES
The scientific interest on MSC as potential therapeutic approach
in neurodegenerative diseases is due to their ability to migrate
to damaged tissues, differentiate and contribute to reparative
processes (Faravelli et al., 2014). Besides these characteristics,
ASC are also easily available and can be used for autologous
transplantation, avoiding possible cell rejection (Marconi et al.,
2013). These properties make ASC a candidate for cell therapy
based on cell replacement and cell differentiation. These features
have led different research groups to use ASC as possible
therapy for ALS. In a study on the effects of ASC systemic
administration in a murine model of ALS we have demonstrated
that the treatment delayed signs of motor deterioration although
a limited amount of ASC in the site of injury was detected
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FIGURE 2 | Hypothetical mechanisms of action of exosomes. Exosomes interact with the endothelial cells of the blood-brain barrier (BBB) modifying the
integrity of cell junctions and increasing the permeability between cells. This mechanism allows a massive entry of vesicles in the central nervous system (CNS). Once
in the CNS, exosomes could interact directly on motoneurons (arrows) modulating different biological processes (such as apoptosis, cell proliferation, gene
expression and oxidative stress) or indirectly modifying the local motoneuron environment, acting on glial cells that decrease the release of toxic factor and
inflammatory mediators (dotted arrows). These direct and indirect mechanisms of action of exosomes could counteract the pathological mechanisms involved in the
disease.
(Marconi et al., 2013). Since the beneficial effects of ASC could
be due to paracrine activity rather than to their engraftment,
the scientific community has shifted the focus from cells to
EVs, which, thanks to their content, can recapitulate the ASC
effects and could potentially provide the basis for a non-cell-
based therapy for the treatment of ALS. This innovative therapy
would be easy to transfer to ALS patients since the EVs would be
obtained from autologous ASC and would preserve the immune
properties of their origins, avoiding immunogenic reaction.
In view of a possible application of EVs to ALS, a disease in
which the BBB is not disrupted, the vesicles need to cross the
BBB to reach the site of injury and, among EVs, exosomes have
the required characteristics. To test the effects of exosomes in
ALS, we have recently demonstrated that the administration of
exosomes in an in vitro model of ALS exerts a neuroprotective
effect following an oxidative insult, supporting the idea that
exosomes can recapitulate and ameliorate the neuroprotective
effect of stem cell therapy (Bonafede et al., 2016).
The evaluation of the exosomes content, in terms of proteins,
mRNAs and miRNAs, and their correlation with a specific
cellular pathway involved in ALS, could pave the way to explain
their mechanism of action. Moreover, the understanding of the
involved pathways could lead to the generation of engineered
cells which release exosomes enriched with specific molecules.
This could lead to a targeted exosome therapy in ALS.
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